← Leaderboards
Richard H Haas
University Of Minnesota
$3,328,082
Attributed
$5,115,852
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $738K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
FDA$3,585,772 · 2
NIH$1,530,080 · 15
By mechanism
R01$3,585,772 · 2
U54$1,298,121 · 3
M01$231,959 · 12
Top collaborators
- Salvatore Dimauro3 shared
- Jeffrey J Gold3 shared
- Cynthia Sharpe3 shared
- John L Thompson3 shared
- Sonya Grace Wang3 shared
Most similar at University Of Minnesota
Same institution · by research overlap
- Kamil Ugurbil$64,679,538
- Antoinette M Moran$24,819,193
- Guisheng Song$3,746,703
- Michael A. Puskarich$3,009,004
- Jeffrey S Miller$32,066,338
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchLactic AcidosisHuman SubjectMetabolism Disorder ChemotherapyMitochondriaUnited States National Institutes Of HealthResearch PersonnelGluconeogenesisGrantPyruvatesInstitutionFundingDisease /Disorder ClassificationChild (0-11)DichloroacetateHuman Therapy EvaluationCellular RespirationMolecular PathologyInborn Metabolism DisorderDrug Screening /EvaluationMitochondrial DiseasesClinicDiagnosticFellowship
Grant awards (61)
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)$703,432
R01 · FY2025 · FD
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)$703,302
R01 · FY2024 · FD
Career Enhancement Program$221,887
U54 · FY2023 · NS · contact PI
NEOLEV3: A Phase IIb Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures of Mild to Moderate Severity IND-109622 (September 6, 2020)$580,471
R01 · FY2022 · FD
Career Enhancement Program$157,550
U54 · FY2022 · NS · contact PI
Career Enhancement Program$157,700
U54 · FY2021 · NS · contact PI
Career Enhancement Program$157,434
U54 · FY2020 · NS · contact PI
Career Enhancement Program$157,500
U54 · FY2019 · NS · contact PI
Phase 2 Study of Levetiracetam for Neonatal Seizures$399,940
R01 · FY2016 · FD · contact PI
Phase 2 Study of Levetiracetam for Neonatal Seizures$399,990
R01 · FY2015 · FD · contact PI
Phase 2 Study of Levetiracetam for Neonatal Seizures$399,062
R01 · FY2013 · FD · contact PI
NAMDC Training$138,304
U54 · FY2013 · NS · contact PI
Phase 2 Study of Levetiracetam for Neonatal Seizures$399,575
R01 · FY2012 · FD · contact PI
NAMDC Training$145,594
U54 · FY2012 · NS · contact PI
NAMDC Training$162,152
U54 · FY2011 · NS · contact PI
LACTIC ACIDEMIA AND MITOCHONDIRAL MYOPATHY$3,797
M01 · FY2010 · RR · contact PI
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS LABORATORY STUDIES$1,553
M01 · FY2010 · RR · contact PI
LACTIC ACIDEMIA AND MITOCHONDIRAL MYOPATHY$9,058
M01 · FY2009 · RR · contact PI
LACTIC ACIDEMIA AND MITOCHONDIRAL MYOPATHY$16,029
M01 · FY2008 · RR · contact PI
PHARMACOKINETICS OF TWO FORMULATIONS OF COENZYME Q10$37,986
M01 · FY2007 · RR · contact PI
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$7,364
M01 · FY2007 · RR · contact PI
PHARMACOKINETICS OF TWO FORMULATIONS OF COENZYME Q10$93,023
M01 · FY2006 · RR · contact PI
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$14,190
M01 · FY2006 · RR · contact PI
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$17,094
M01 · FY2005 · RR
Lactic Acidemia and Its Clinical Counterparts$31,865
M01 · FY2004 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2002 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2002 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2002 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2002 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2002 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2002 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2002 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2002 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2002 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2001 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2001 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2001 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2001 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2001 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2001 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2001 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2001 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2000 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2000 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2000 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2000 · RR
LACTIC ACIDEMIA AND ITS CLINICAL COUNTERPARTS$0
M01 · FY2000 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2000 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2000 · RR
MITOCHONDRIAL MECHANISM IN HUMAN LACTIC ACIDOSIS$0
M01 · FY2000 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2000 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2000 · RR
DICHLOROACETATE IN CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2000 · RR
DICHLOROACETATE IN TREATMENT OF CONGENITAL LACTIC ACIDEMIA$0
M01 · FY2000 · RR